The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 129% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 403%. Our forward projection puts the odds of a 10% gain over the next month near 34%.
Rallybio Corp RLYB
Outside both standardsAn entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
read at $16.42
Rallybio Corp holds its Accumulation at $16.42.
- PHPhase · the trend structure carries the Accumulation label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · does not pass the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 2 days |
| Price | $16.42 |
| Valuation | N/A trailing · -3.04 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | -0.89 |
The business, in plain words · what the numbers mean
| Forward P/E | -3.0x |
| Revenue growth | 0.0% revenue is shrinking |
| Profit margin | 0.0% currently unprofitable |
| Return on equity | -15.0% not currently earning a positive return on equity |
| Debt to equity | 0.31 minimal debt — a conservative balance sheet |
| Current ratio | 12.92 comfortably covers its short-term bills |
| Beta | -0.89 barely tracks the market's swings |
| Market cap | $87M |
| Employees | 14 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in RLYB's space worth a look
Screened names in the same industry · explore each on its own page.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 129% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 403%. Our forward projection puts the odds of a 10% gain over the next month near 34%.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $14.00 | +13.9% | · | $1,139 | +13.9% |
| 2 months | $8.44 | +88.9% | · | $1,889 | +88.9% |
| 3 months | $9.60 | +66.0% | · | $1,660 | +66.0% |
| 6 months | $5.94 | +168.5% | · | $2,685 | +168.5% |
| 1 year | $3.17 | +403.2% | · | $5,032 | +403.2% |
| 2 years | $12.20 | +30.7% | · | $1,307 | +30.7% |
| 3 years | $63.12 | -74.8% | · | $253 | -74.8% |
Historical returns from market close data. Past performance does not guarantee future results.